AKT1 and B-cell non-Hodgkin lymphoma: Eμ-Myc HPCs with AKT: pre-B-cell lymphomas with 100% incidence at 12 weeks. Resistant to doxorubicin and rapamycin but sensitive to combination treatment (63)